PTGX
HEALTHCAREProtagonist Therapeutics Inc
AI Insight
What's Moving PTGX Today?
No stock-specific AI insight has been generated for PTGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$49.38$119.85
$124.80
Fundamentals
Market Cap$7.6B
P/E Ratio—
EPS$-1.81
Dividend Yield—
Dividend / Share—
ROE-17.1%
Profit Margin-154.9%
Debt / Equity—
Trading
Volume515K
Avg Volume (10D)—
Shares Outstanding64.3M
PTGX News
24 articles- Protagonist Therapeutics Reports Granting of Inducement AwardsYahoo Finance·Jun 16, 2026
- Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide RallyAlphaStreet·Jun 4, 2026
- Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association CongressYahoo Finance·Jun 1, 2026
- Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%Motley Fool·May 30, 2026
- Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million MoreMotley Fool·May 30, 2026
- Protagonist Therapeutics (PTGX) Stock Forecast & Analyst RatingsMoomoo·May 29, 2026
- J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?Wall Street Journal·May 28, 2026
- Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026Yahoo Finance·May 28, 2026
- Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.comInvesting.com Canada·May 21, 2026
- Hedge Fund Wagers $36 Million on Biotech Denali After First FDA ApprovalMotley Fool·May 18, 2026
- Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?Motley Fool·May 18, 2026
- Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?Motley Fool·May 18, 2026
- Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging HigherYahoo Finance·May 11, 2026
- Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsYahoo Finance·May 8, 2026
- Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?Yahoo Finance·May 7, 2026
- Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This StockYahoo Finance·May 2, 2026
- Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationYahoo Finance·Apr 28, 2026
- Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This StockYahoo Finance·Apr 27, 2026
- High Growth Tech Stocks To Watch In US April 2026Yahoo Finance·Apr 24, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- How to Play J&J Stock Post a Beat-and-Raise Performance in Q1Yahoo Finance·Apr 20, 2026
- Growth vs. Stability: Lilly and J&J's 2026 Investment Face-OffYahoo Finance·Apr 13, 2026
- This Healthcare Stock Barely Flinches During Market Sell-OffsThe Motley Fool·Apr 2, 2026
All 24 articles loaded
Price Data
Open$119.38
Previous Close$118.96
Day High$124.80
Day Low$118.81
52 Week High$119.85
52 Week Low$49.38
52-Week Range
$49.38$119.85
$124.80
Fundamentals
Market Cap$7.6B
P/E Ratio—
EPS$-1.81
Dividend Yield—
Dividend / Share—
ROE-17.1%
Profit Margin-154.9%
Debt / Equity—
Trading
Volume515K
Avg Volume (10D)—
Shares Outstanding64.3M
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—